Mid Penn Bancorp (NASDAQ:MPB) reported quarterly earnings of $0.93 per share. This is a 14.81 percent increase over earnings of $0.81 per share from the same period last year.
Xenpozyme Approved By FDA As First Disease-Specific Treatment For ASMD
Paris, August 31, 2022. The U.S. Food and Drug Administration (FDA) has approved XenpozymeTM (olipudase alfa-rpcp) for the treatment of non-central nervous system (non-CNS) manifestations of acid sphingomyelinaseParis, August 31, 2022. The U.S.
